Shares of Blueprint Medicines (BPMC) have risen by 240% since my December 2016 article called the company "a nascent leader in the targeted oncology space". The stock has gained just 16% since my December 2017 update suggested that readers "buy the secondary".
Lately, I was impressed by data shared at the ASCO (American Society of Clinical Oncology) Annual Meeting for BLU-667 in RET-altered cancers, showing activity even in patients who'd already been treated with LOXO-292 (from Loxo Oncology which was acquired by Eli Lilly (LLY) in an $8 billion deal). Couple that with